MDMA
In findings presented at the American Chemical Society’s (ACS) Spring Meeting for 2022, researchers reported on follow-up results form a Phase III 2021 trial in which MDMA was paired with therapy and tested for the treatment of PTSD.
The 2021 trial indicated significant efficacy for the treatment: after only three sessions, patients given MDMA during therapy were 35% less likely to meet the diagnosis for PTSD than those given a placebo.
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
